SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Lindbäck Stefan)
 

Sökning: WFRF:(Lindbäck Stefan) > Antiretroviral trea...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00003934naa a2200517 4500
001oai:gup.ub.gu.se/58176
003SwePub
008240910s2006 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:1938046
0247 a https://gup.ub.gu.se/publication/581762 URI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:19380462 URI
0247 a https://doi.org/10.1080/003655405003888342 DOI
040 a (SwePub)gud (SwePub)ki
041 a eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Gisslén, Magnus,d 1962u Gothenburg University,Göteborgs universitet,Institutionen för biomedicin, avdelningen för infektionssjukdomar,Institute of Biomedicine, Department of Infectious Medicine4 aut0 (Swepub:gu)xgissm
2451 0a Antiretroviral treatment of HIV infection: Swedish recommendations 2005.
264 1b Informa UK Limited,c 2006
520 a On 2 earlier occasions, in 2002 and 2003, the Swedish Medical Products Agency (MPA) and the Swedish Reference Group for Antiviral Therapy (RAV) have jointly publicized recommendations for the treatment of HIV infection. A working group from the same expert team that produced the 2002 report has now revised the text again. Since the publication of the last treatment recommendations, 4 new medicines have become available: emtricitabine, atazanavir, fosamprenavir, and enfuvirtid. The last-mentioned belongs to a new class of HIV medications called fusion inhibitors (Box 1). It is likely that tipranavir will also be on the market soon. Simultaneously, the drug zalcitabin has been deregistered. The following updated recommendations parallel the earlier ones, but increased knowledge allows us to be more specific in our recommendations. Thus, it is now suggested that the initial treatment for HIV infection consist of 2 nucleoside reverse transcriptase inhibitors (NRTIs) and 1 non-nucleoside reverse transcriptase inhibitor (NNRTI); or 2 NRTIs and 1 protease inhibitor (PI). In the group of the NRTIs, stavudine is no longer recommended for this purpose. In the NNRTI group, efavirenz should be preferred to nevirapine, except under special circumstances. Finally, PIs ought to be boosted with ritonavir (PI/r). Also new are recommendations regarding treatment choices for patients co-infected with hepatitis B virus (HBV) or tuberculosis (TB). As in the case of the previous publication, recommendations are evidence-graded in accordance with the Oxford Centre for Evidence Based Medicine, 2001 (see http://www.cebm.net/levels_of_evidence.asp#levels), and have been supplemented with references to newly-added sections and data not referred to in earlier background documentation.
653 a Anti-Retroviral Agents
653 a adverse effects
653 a classification
653 a therapeutic use
653 a CD4 Lymphocyte Count
653 a Food-Drug Interactions
653 a HIV Infections
653 a drug therapy
653 a Hepatitis C
653 a drug therapy
653 a Humans
653 a Sweden
7001 a Ahlqvist-Rastad, Jane4 aut
7001 a Albert, Janu Karolinska Institutet4 aut
7001 a Blaxhult, Andersu Karolinska Institutet4 aut
7001 a Hamberg, Anna-Karin4 aut
7001 a Lindbäck, Stefan4 aut
7001 a Sandström, Ericu Karolinska Institutet4 aut
7001 a Uhnoo, Ingrid4 aut
7001 a Sonnerborg, Au Karolinska Institutet4 aut
7102 a Göteborgs universitetb Institutionen för biomedicin, avdelningen för infektionssjukdomar4 org
7730 t Scandinavian journal of infectious diseasesd : Informa UK Limitedg 38:2, s. 86-103q 38:2<86-103x 0036-5548x 1651-1980
8564 8u https://gup.ub.gu.se/publication/58176
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:1938046
8564 8u https://doi.org/10.1080/00365540500388834

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy